Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction April 29, 2025
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) April 22, 2025
MEDICUS PHARMA LTD ANNOUNCES POSITIVELY TRENDING INTERIM ANALYSIS FOR SKNJCT-003 PHASE 2 CLINICAL STUDY TO NON-INVASIVELY TREAT BASAL CELL CARCINOMA OF THE SKIN (BCC) March 6, 2025
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) February 27, 2025